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Abstract
We introduce and evaluate data analysis methods to interpret simultaneous measurement of multiple genomic
features made on the same biological samples. Our tools use gene sets to provide an interpretable common scale
for diverse genomic information. We show we can detect genetic effects, although they may act through different
mechanisms in different samples, and show we can discover and validate important disease-related gene sets that
would not be discovered by analyzing each data type individually.
Background
The increasing affordability of high throughput genome-
wide assays is enabling the simultaneous measurement
of several genomic features in the same biological sam-
ples. Cancer genome projects have been at the forefront
of this trend, and have faced the challenge of integrating
these diverse data types [1,2], including RNA transcrip-
tional levels, genotype variation, DNA copy number var-
iation, and epigenetic marks. Annotated collections of
gene sets, capturing established knowledge about biolo-
gical processes and pathways, have proven an essential
tool for integration. Examples of these sets include chro-
mosomal locations, signaling and metabolic pathways,
transcriptional programs, and targets of specific tran-
scription factors. Because one can make inferences
about the importance of a given gene set using several
different genomic data types, gene set analysis provides
a direct and biologically motivated approach to analyz-
ing these data types in an integrated way. A widely used
public collection of gene sets is the Molecular Signa-
tures Database (MSigDb) [3]. A comprehensive list of
conventional tools for gene set analysis for a single data
type is given in Ackermann et al.[ 4 ] .M a n yo ft h e s e
approaches are implemented in the extensively used sta-
tistical computing environment R/Bioconductor [5].
The gene set perspective makes sense both biologically
and statistically. First, small differences in the functions
of multiple genes in the same set may not be detectable
at the single gene level, but can add to create larger dif-
ferences at the gene set level. This increases the power
for detecting real biological differences. Second, a single
hit on a given pathway may be sufficient to generate a
phenotypic difference. If this hit can occur in any of sev-
eral components in the pathway, individuals with the
same phenotype may show variability in the specific
genes that are hit, but show a more consistent pattern
at the pathway or gene set level [1,6]. Importantly, even
w h e nad i f f e r e n c ea tt h es i n g l eg e n el e v e lc a nb e
detected, its biological importance may depend on the
states of other interacting genes and gene products.
Cancer genomes contain point mutations, insertions,
deletions, translocations, methylation abnormalities, and
copy number (CN) and expression changes not seen in
normal tissues. In some cancers, such as glioblastoma
multiforme (GBM), different genes involved in pathways
involving TP53, phosphoinositide 3-kinase (PI3K), and
RB1 are altered in different patients, and, importantly,
these might be altered via different mechanisms [1],
such as point mutations and CN changes. Therefore,
taking into account multiple data types should improve
our ability to detect gene sets associated with a
phenotype.
In recent large-scale cancer genome studies [1,6,7]
preliminary integration approaches have been success-
fully applied; however, these approaches have been tai-
lored to specific contexts. A general, a scalable and
rigorous statistical framework has not yet been devel-
oped. In this article, our goal is to fill this gap. To this
end, we introduce, compare, and systematically evaluate
two alternative set-based data integration approaches.
The first approach is based on computing model-based
gene-to-phenotype association scores for each gene
using all data types together, followed by gene set analy-
sis of these scores. We term this the integrative
* Correspondence: gp@jimmy.harvard.edu
1Department of Biostatistics and Computational Biology, Dana-Farber Cancer
Institute, 450 Brookline Avenue, Boston, MA 02115, USA
Full list of author information is available at the end of the article
Tyekucheva et al. Genome Biology 2011, 12:R105
http://genomebiology.com/2011/12/10/R105
© 2011 Tyekucheva et al.; licensee BioMed Central Ltd. This is an open access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.approach. The second is to perform separate conven-
tional gene set analyses for each data type, and then
derive a consensus significance score using a meta-ana-
lytical approach.
Results
Overview
We present both novel data analyses and controlled
simulations. First, we jointly examine gene expression
and CN variation data about glioblastoma multiforme
tumors from The Cancer Genome Atlas (TCGA) [2],
and detect differences in the Wnt, glycolysis and stress
pathways that appear relevant to differences between
short- and long-term survivors. We also validate these
findings using independent samples from the NCI Repo-
sitory for Molecular Brain Neoplasia Data (Rembrandt)
[8]. To provide a rigorous counterpart to these results
we perform extensive simulations. These show that the
integrative approach does enable the discovery of dis-
ease-related gene sets that would not be discovered
when each data type is analyzed individually using cur-
rent approaches. Discoveries remain reliable also when
several features are highly noisy.
The Cancer Genome Atlas glioblastoma multiforme study
We consider TCGA glioblastoma data [2] of four types:
two gene expression measurements (E1, E2) and two
CN measurements (C1, C2), described in Materials and
methods. To discover gene sets important in GBM sur-
vival we use an extreme discordant phenotype design
[9] with a total of 95 subjects. GBM patients with a sur-
vival time shorter than the lower quartile (190 days) are
labeled short-term survivors (STSs), and those with a
survival time longer than the upper quartile (594 days)
long-term survivors (LTSs). Such grouping enhances sig-
nal relevant to survival. We used gene sets from the
MSigDb canonical pathways.
First, we consider genes that are measured in all data
types (genes that are measured only in a subset of plat-
forms are filtered out), and use a competitive gene set
test (see Materials and methods), comparing genes within
a set to the remainder of the annotated genes. The 30 top
sets discovered by the integrative approach are reported
in Table 1. If we consider the top 30 sets, we discover 12
gene sets that are not discovered by any of the standard
single-data-type analyses. The majority of these sets are
related to metabolic processes. Six are involved in sugar-
related metabolic processes and energy production, and
two (the curated streptomycin biosynthesis pathway, and
its KEGG (Kyoto Encyclopedia of Genes and Genomes)
counterpart, hsa00521) are identified as a result of genes
shared with the sugar metabolism group (six out of eight
genes in the streptomycin biosynthesis set are paralogs of
genes in the glycolysis pathway).
This metabolic shift toward sugar metabolism is not
surprising since it is known that cancer cells in general
[10,11], and glioblastoma cells in particular [11], depend
on the conversion of glucose to lactate in the presence
of oxygen (Warburg effect [12]). It has also been shown
that shutdown or down-regulation of the glycolysis
pathway in glioblastoma is associated with cell death
[13,14].
We find that mean measurements for glycolytic genes
are, on average, larger in the STS compared to the LTS
phenotype (Figure 1) and that there are more gene
copies in STSs. Since reduced glycolysis (and sugar
usage) promotes GBM cell death, we speculate that
there might be an association between patient survival
and efficient sugar metabolism, which is being detected
by the integrative approach but missed by conventional
analysis of each data type separately.
Necrosis and hypoxia are pathognomonic features of
the highest-grade malignant gliomas and are thought to
p l a yak e yr o l ei nt h ea g g r e s s i v eb e h a v i o ro fG B M ,
including invasiveness and chemo-resistance, through a
variety of mechanisms [15-17]. The induction of the gly-
colytic pathway we have documented in STS patients is
likely to represent an adaptive consequence of hypoxic
conditions, mediated by genomic alteration and/or
expression of hypoxia inducible factors (HIF1A and
HIF2A), which have been shown to induce glycolytic
genes [18], and recently to play a fundamental role in
the expansion and maintenance of the GBM stem cell
compartment [19,20].
The other metabolic processes related to gene sets
identified in our analysis are riboflavin (vitamin B2)
metabolism and the biosynthesis of glycosphingolipid.
The involvement of the riboflavin pathways appears to
be mostly driven by up-regulation of members of the
myotubularin-related protein family (not shown), which
act as phosphatases modifying cell membrane phospho-
lipids. From this perspective, the concomitant enrich-
ment of ‘biosynthesis of glycosphingolipid’,m o s t l y
determined by gene down-regulation at both the CN
and expression level (not shown), may relate to an early
observation that membrane lipid modifications occur
during progression of human gliomas [21], and that gly-
cosphingolipid profiles correlate with survival grading in
human gliomas [22]. Intriguingly, a crucial role for the
PI3K/AKT pathway in the regulation of lipid biosynth-
esis and signaling pathways was recently reported [23],
linking our findings to the major molecular alterations
in the PI3K pathway in GBM identified in TCGA [2].
Among the non-metabolic gene sets detected in our
analysis, we highlight those associated with the stress and
Wnt pathways. The stress pathway includes genes
involved in TNF signaling through its receptors TNFR1
and TNFR2. Cellular responses to TNF encompass a
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apoptosis. The final outcome results from the modula-
tion, integration and cross-talk of distinct signaling cas-
cades that are initiated by TRADD (TNFR1-associated
DEATH domain protein) and TRAF2 (TNF receptor-
associated factor 2) [24,25]. The presence of this gene set
in our analysis is mostly driven by increased expression/
CN of pathway members in the STS phenotype (Figure
1). Factors involved in both survival and apoptosis are
increased (that is, mitogen-activated protein kinase
(MAPK) signaling pathway genes NFKB1, TRADD,
CRADD (CASP2 and RIPK1 domain containing adaptor
with death domain)). The only two genes with reduced
expression in the STS group are those encoding TNF,
which initiates the signaling, and MAPK8, which is
required for TNF-alpha-induced apoptosis [26].
Although extensive evidence has been published
describing the Wnt pathway’sr o l ei ne m b r y o n i c
development, adult tissue homeostasis, and human dis-
ease, including cancer [27], little is know about the role
of the Wnt pathway in GBM. However, recent findings
have shown that promoter hypermethylation of Wnt
pathway inhibitors occurs in GBM [28]. In our analysis,
the relationship of the Wnt pathway to survival in GBM
patients is driven by both increased and decreased
expression/CN in the STS group (Figure 1) of genes
encoding both inhibitors and activators of the Wnt
pathway. ‘Up-regulated’ genes include central players of
the pathway, specifically CTNNB1 (encoding b-catenin)
and GSK3B (glycogen synthase kinase 3 beta). GSK3
phosphorylates the APC/AXIN1/CTNNB1 complex, and
thus targets b-catenin for degradation. Wnt signaling
activation determines GSK3 inhibition status, resulting
in b-catenin stabilization, nuclear transfer and transcrip-
tion activation. These results agree with the recent
observation that GSK3 inhibition results in glioma cell
Table 1 P-values for top 30 gene sets discovered by the integrative method using the competitive gene sets test
Pathway E1 E2 C1 C2 INT
AMINOSUGARS_METABOLISM* 0.0132 0.4429 0.4686 0.0085 0.0008
STREPTOMYCIN_BIOSYNTHESIS 0.1180 0.0822 0.8774 0.1301 0.0024
STARCH_AND_SUCROSE_METABOLISM* 0.0163 0.0457 0.6400 0.7045 0.0048
TRANSLATION_FACTORS 0.0006 0.0007 0.0700 0.0505 0.0092
HSA00860_PORPHYRIN_AND_CHLOROPHYLL_METABOLISM 0.0034 0.1760 0.1306 0.1287 0.0098
GLYCOLYSISPATHWAY* 0.1321 0.2590 0.1119 0.0716 0.0105
HSA00624_1_AND_2_METHYLNAPHTHALENE_DEGRADATION 0.0157 0.0037 0.3096 0.4940 0.0115
HSA03050_PROTEASOME < 10
-4 0.0021 0.7431 0.9031 0.0123
HSA00521_STREPTOMYCIN_BIOSYNTHESIS 0.1243 0.1364 0.9467 0.2227 0.0124
HSA00530_AMINOSUGARS_METABOLISM* 0.0123 0.2232 0.8209 0.2205 0.0130
FRUCTOSE_AND_MANNOSE_METABOLISM* 0.2724 0.6586 0.2115 0.0618 0.0140
STRESSPATHWAY 0.3783 0.0589 0.0636 0.0533 0.0175
HSA00500_STARCH_AND_SUCROSE_METABOLISM* 0.0328 0.3084 0.7397 0.8215 0.0188
HSA00740_RIBOFLAVIN_METABOLISM 0.3108 0.1873 0.6021 0.1767 0.0198
PORPHYRIN_AND_CHLOROPHYLL_METABOLISM 0.0444 0.1849 0.3903 0.0703 0.0206
HSA00603_GLYCOSPHINGOLIPID_BIOSYNTHESIS_GLOBOSERIES 0.3816 0.4798 0.2583 0.1846 0.0230
KREBS_TCA_CYCLE 0.3707 0.0663 0.3670 0.0117 0.0246
IL10PATHWAY 0.0391 0.0166 0.1396 0.0650 0.0263
BLOOD_GROUP_GLYCOLIPID_BIOSYNTHESIS_LACTOSERIES 0.0070 0.3230 0.4054 0.6334 0.0268
HSA00642_ETHYLBENZENE_DEGRADATION 0.0263 0.0198 0.1641 0.4937 0.0306
FEEDERPATHWAY* 0.1347 0.2727 0.2331 0.4541 0.0312
GALACTOSE_METABOLISM* 0.1987 0.2374 0.5055 0.0538 0.0333
CYTOKINEPATHWAY 0.0238 0.0439 0.1226 0.2484 0.0400
WNTPATHWAY 0.8890 0.2008 0.3227 0.0549 0.0402
HSA00051_FRUCTOSE_AND_MANNOSE_METABOLISM* 0.5893 0.7157 0.3759 0.0078 0.0408
GLYCOSAMINOGLYCAN_DEGRADATION* 0.0135 0.4210 0.0348 0.0208 0.0464
GLUCONEOGENESIS* 0.1634 0.0849 0.7657 0.5843 0.0488
GLYCOLYSIS* 0.1634 0.0849 0.7657 0.5843 0.0488
PROTEASOMEPATHWAY 0.0015 0.0702 0.6308 0.7039 0.0497
HSA00052_GALACTOSE_METABOLISM* 0.2507 0.4202 0.5990 0.0354 0.0497
The sets discovered using integration but not using any of the single-data-type analyses are in bold font. An asterisk denotes sets related to sugar metabolic
processes. Discoveries are sets whose P-value is < 0.05. E1 and E2, single data type analysis using expression data; C1 and C2, single data type analysis using
copy number data; INT, integrative method.
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Figure 1 Heatmaps of the two sample t-statistic from each data type between long- and short-term survival phenotypes.C o l o rk e y s
larger than 1.9 or smaller than -1.9 approximate statistical significance of the difference. Positive t-statistic means higher average measurements
for short-term survivors.
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activation, decreased NF-B activity, and an alteration
of intracellular glucose metabolism [29]. Even more
interesting is that increases of GSK3 and NFKB1 in the
STS group, at both the CN and expression level, are
accompanied by decreased MYC levels (Figure 1).
To assess the sensitivity of our results to the choice of
patients, we considered tertiles instead of quartiles, and
we used a gene-level Cox regression model on the entire
patient set. The results were very similar to those pre-
sented above (Tables S1 and S2 in Additional file 1).
Our gene-to-phenotype association scores are based on
the difference of the deviances in the gene-level regression
model. This metric depends on the number of variables
included in the model. As the number of variables
increases, the difference of the deviances will grow, even if
the added variables are not truly correlated with the phe-
notype, and thus do not provide any additional biological
signal. Therefore, competitive gene set tests cannot be
used to analyze genes that are not measured for all data
types because the genes that are measured on fewer plat-
forms will get inferior rankings when compared to genes
that might have the same strength of biological signals but
are measured everywhere. However, restricting attention
to the genes measured in all data types might lead to loss
of some interesting biological information. We extended
our analysis to the union of genes measured in at least one
data type. To do this without biasing the results in favor of
genes represented in multiple data types, we use a self-
contained gene set test (see Materials and methods), com-
paring genes within each set to a null distribution based
on those genes only. This test compares the observed data
to an internal control based on the null distribution for
the same set of genes: thus, the values for each gene under
the null hypothesis account for the number of data types
for which the gene is available, and the effect of the num-
ber of platforms on the association scores is properly con-
trolled. The results are given in Table 2. The top sets
share pathways with the competitive analysis, including
sugar metabolic processes. Interestingly, the second most
significant pathway (HSA04010_MAPK_SIGNALING)
contains all the genes from the STRESSPATHWAY
reported above. Smaller P-values and rearrangements in
the list of top sets for the self-contained test, compared to
the competitive one, are likely to result mostly from the
different statistical meaning of the test (the two proce-
dures test different null hypotheses).
Independent validation
We validated results by applying the same method to an
independent set of glioblastoma samples from the
Rembrandt database [8]. Because we could only acquire
information on a relatively limited number of genes, we
focused on validation of the top 30 sets emerging from
the self-contained analysis. Despite smaller sample sizes,
missing genes, and the availability of only two data
types, the vast majority of the pathways discovered in
TCGA show strong evidence of association with survival
in our validation set (Table 2), and the directions of
association are generally confirmed.
Simulations
To generate data as realistic as possible, we began with
the actual TCGA GBM data just described, reassigned
phenotype labels at random, spiked in gene set differ-
ences, and asked each method to recover the set that
h a db e e ns p i k e di n .W eu s e db o t hs y n t h e t i cn o n - o v e r -
lapping gene sets and real chromosomal bands to cap-
ture both low and high within-set correlations. In each
spike-in experiment we set a fraction g of genes to be
truly associated with the phenotype within a spiked-in
set, and a strength b o ft h ee f f e c to ft h eg e n eo nt h e
phenotype. We varied g and b to generate alternative
scenarios (see Materials and methods for details).
Synthetic gene sets
Our synthetic gene set collection mimics the size distribu-
tion of sets from the MSigDb canonical pathway collection
[3]. Genes are assigned to sets at random, but so that sets
in the collection do not share genes. Therefore, we do not
expect two genes within a set to be more strongly corre-
lated than any two genes not belonging to the same set.
We perform gene set analysis on all data types sepa-
rately, using a standard methodology implemented in
the limma package in Bioconductor [5,30]. We compare
these to three multi-platform methods. For each method
we rank sets by P-value, and select the top ten. We eval-
uate approaches by comparing the number of true posi-
tive hits among the top ten sets (Figure 2a). Results
from the four individual data types are practically indis-
tinguishable. All three multiple-data-type approaches
outperform the single-data-type approaches. The inte-
grative approach is significantly better for small values
of g, where subsets of altered genes are likely to be dif-
ferent across data types. In such settings the sensitivity
of single-data-type methods will be relatively low, but
the integrative approach enjoys increased sensitivity
because the integrated gene-to-phenotype association
score is sensitive to gene alterations in a single data
type. This property is especially useful when genes in a
certain set are altered by different biological mechan-
isms, and consequently measured via different data
types. Both meta-analytical approaches perform simi-
larly, and are outperformed by the integrative approach.
This pattern of performance is similar for other values
of b. All methods, as expected, perform better as b
increases (not shown).
Figure 2b shows receiver operating characteristic
(ROC) [31] curves from the same simulations to provide
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approach tends to have the highest sensitivity and speci-
ficity across all P-value cutoffs. Accuracy results are
summarized using areas under the ROC curves in Table
3. Importantly, the integrative approach generally shows
less variability when compared to both single-data-type
approaches and meta-analysis.
Chromosome bands
Our next gene set collection is defined by the chromo-
somal location of genes, and constitutes a partition of
the genes measured. Here we expect mildly increased
correlations within the sets for gene expression, as well
as strong spatial correlations within sets, and between
physically neighboring sets for the CN.
The performance of single-data-type approaches dif-
fers between expression and CN (Figure 2a). The strong
spatial correlations between neighboring bands are
inherited from the data that we use to construct our
simulations. In the GBM tumor samples, amplifications
and deletions tend to be large, sometimes spanning sev-
eral chromosome bands, and are present only in subsets
of patients. Because of that, the variability of the Wil-
coxon test ranks for CN data tends to be much lower
for neighboring bands than for randomly selected ones.
Therefore, false positive calls for CN data tend to cluster
by their ranks and chromosomal position. This explains
the inferior performance when compared to expression
data, which are not affected as much by spatial correla-
tions. In contrast, mild correlations within the sets for
expression data tend to aid discovery of the spiked-in
sets. Both expression data types perform better for the
chromosome band collection than for the synthetic sets,
where genes within sets were not correlated. Since both
CN data types tend to produce a large amount of false
positive calls in the top ten list, the performance of inte-
gration methods may also deteriorate. The most affected
Table 2 P-values for top 30 gene sets discovered by the integrative method using the self-contained gene sets test
Pathway E1 E2 C1 C2 INT INT for validation set
HSA04810_REGULATION_OF_ACTIN_CYTOSKELETON 0.0697 0.2250 < 10
-4 <1 0
-4 <1 0
-4 0.0001
HSA04010_MAPK_SIGNALING_PATHWAY 0.1302 0.0746 < 10
-4 <1 0
-4 <1 0
-4 <1 0
-4
HSA04060_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION 0.1422 0.0132 < 10
-4 <1 0
-4 <1 0
-4 0.0147
HSA04310_WNT_SIGNALING_PATHWAY 0.2389 0.0039 < 10
-4 <1 0
-4 <1 0
-4 0.0001
HSA04080_NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION 0.1164 0.8695 0.0001 0.0005 < 10
-4 0.0042
HSA00230_PURINE_METABOLISM 0.0034 0.0503 0.0000 0.0003 < 10
-4 0.0022
TRANSLATION_FACTORS 0.0208 0.0155 0.0022 0.0052 0.0001 0.2711
HSA01030_GLYCAN_STRUCTURES_BIOSYNTHESIS_1 0.0781 0.0292 0.0004 0.0003 0.0001 0.0454
HSA04360_AXON_GUIDANCE 0.4293 0.1803 < 10
-4 0.0106 0.0001 0.0001
GLUCONEOGENESIS* 0.0435 0.1010 0.0613 0.0106 0.0001 0.0409
GLYCOLYSIS* 0.0435 0.1010 0.0613 0.1065 0.0001 0.0409
HSA00500_STARCH_AND_SUCROSE_METABOLISM* 0.0448 0.2669 0.0140 0.0043 0.0001 0.0364
HSA04630_JAK_STAT_SIGNALING_PATHWAY 0.2975 0.0090 0.0022 0.0041 0.0002 0.0141
HSA04510_FOCAL_ADHESION 0.0423 0.0926 0.0042 0.0374 0.0002 10
-4
MRNA_PROCESSING_REACTOME 0.1660 0.0062 0.0537 0.0004 0.0003 < 10
-4
HSA05215_PROSTATE_CANCER 0.0534 0.3618 0.0013 0.0534 0.0004 0.0008
HSA01031_GLYCAN_STRUCTURES_BIOSYNTHESIS_2 0.0084 0.0076 0.0312 0.0141 0.0004 0.0926
HSA00240_PYRIMIDINE_METABOLISM 0.0013 0.0307 0.0022 0.0065 0.0004 0.0063
HSA04210_APOPTOSIS 0.1207 0.2064 0.0003 0.0001 0.0004 0.0021
HSA04620_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY 0.1986 0.1228 0.0001 0.0109 0.0004 0.0006
GLYCOLYSIS_AND_GLUCONEOGENESIS* 0.0209 0.1407 0.0476 0.0112 0.0005 0.1808
HSA04660_T_CELL_RECEPTOR_SIGNALING_PATHWAY 0.0192 0.1176 0.0141 0.0027 0.0006 0.0661
HSA00051_FRUCTOSE_AND_MANNOSE_METABOLISM* 0.1565 0.2238 0.0314 0.0112 0.0006 0.2631
HSA00010_GLYCOLYSIS_AND_GLUCONEOGENESIS* 0.0515 0.1333 0.1276 0.0148 0.0007 0.0647
INTEGRIN_MEDIATED_CELL_ADHESION_KEGG 0.2779 0.1734 0.0017 0.0038 0.0007 0.0001
HSA04640_HEMATOPOIETIC_CELL_LINEAGE 0.0634 0.0676 0.0140 0.0009 0.0007 0.0026
GPCRDB_CLASS_A_RHODOPSIN_LIKE 0.3429 0.4710 0.0003 0.0483 0.0008 0.0449
HSA00350_TYROSINE_METABOLISM 0.0219 0.0421 0.0772 0.0085 0.0008 0.0648
HSA05221_ACUTE_MYELOID_LEUKEMIA 0.0697 0.3196 0.0213 0.0105 0.0009 0.0310
CALCINEURIN_NF_AT_SIGNALING 0.1302 0.1298 0.0205 0.0005 0.0010 0.1128
Asterisks indicate sets related to sugar metabolic processes. E1 and E2, single data type analysis using expression data; C1 and C2, single data type analysis using
copy number data; INT, integrative method.
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because when there is a disagreement between data
types, the strongest signal is not necessarily correct.
Averaging P-values leads to a better, but still unsatisfac-
tory, performance. The integrative approach is affected
the least by the poor performance of the autocorrelated
CN data. It still performs best for small and intermedi-
ate values of g, which are the most common. In practice,
we may not know which data type is best at capturing
the signal, in which case using an integrative approach
provides a robust safe analytical plan. The ROC curves
(Figure 2b) show that as a higher sensitivity is sought,
the integration method still retains a substantial edge
over the single-data-type methods. The performance of
the meta-analytical methodsi m p r o v e sa n de v e n t u a l l y
approaches that of individual expression data, though it
remains inferior to integration. Average areas under
ROC curves are in given in Table 3.
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Figure 2 Simulation results. (a) Average number of discovered spiked-in sets among the top ten sets that are inferred to be enriched for
genes discriminating between two phenotypes, against the expected fraction of the altered genes; b = 0.5. (b) Average ROC curves; b = 0.5, g =
0.1. INT, integrative method.
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The MSigDb canonical pathway collection differs from
the previous two in that it is not a partition of genes.
Thus, we expect to observe correlations within the sets,
for biological reasons such as co-regulation, and
between the sets, because they share common genes. In
terms of our simulation study, an important issue is
how to define a true positive call. When we spike-in
preselected sets, we may also alter other sets that con-
tain genes that were chosen to be associated with the
phenotype. Recovering such unintentional spike-in sets
should not necessarily be considered as a false positive.
To account for this, we consider a discovered set to be
a true positive if it shares at least 50% of the genes with
the union of genes from the original spike-in sets.
All methods perform worse than before. This is par-
tially explained by the difficulty of defining a true
positive. Multi-data-type methods provide gains in per-
formance of various magnitudes for almost all scenarios.
For all b, with g ≥ 0.9, the average P-value method mar-
ginally outperforms the integrative approach. The varia-
bility of the accuracy of the methods also slightly
increases compared to the previous scenarios (Table 3).
Novel discoveries
Individual data types rank sets differently, discovering
different sets for a given list size. Figure 3a shows the
fraction of sets that are exclusively discovered by each
data type. Figure 3b shows the additional sets discovered
by the integrative and meta-analytical approaches but
n o tb ya n yo ft h es i n g l e - d a t a - t y p ea n a l y s e s( s e eM a t e r i -
als and methods for details). The meta-analytical
approaches show minimal improvement over single-
d a t a - t y p ea n a l y s i s ,w h i l et h ei n t e g r a t i v em e t h o d
Table 3 Areas under the ROC curves for various simulation scenarios
Method
bg E1 C1 INT AvgP MinP
Synthetic gene sets
0.166 0.1 0.59 (0.1) 0.58 (0.09) 0.84 (0.07) 0.65 (0.09) 0.64 (0.09)
0.5 0.83 (0.1) 0.79 (0.1) 0.98 (0.03) 0.91 (0.06) 0.89 (0.06)
1 0.94 (0.07) 0.92 (0.07) 0.97 (0.03) 0.98 (0.03) 0.97 (0.03)
0.5 0.1 0.69 (0.09) 0.7 (0.09) 0.96 (0.03) 0.80 (0.07) 0.77 (0.07)
0.5 0.94 (0.05) 0.94 (0.05) 1 (0.01) 0.99 (0.02) 0.98 (0.02)
1 0.99 (0.02) 0.99 (0.01) 1 (0.01) 1 (0.01) 1 (0.01)
0.84 0.1 0.73 (0.08) 0.74 (0.08) 0.98 (0.02) 0.85 (0.06) 0.81 (0.07)
0.5 0.97 (0.03) 0.97 (0.03) 1 (0) 1 (0.01) 0.99 (0.01)
1 1 (0) 1 (0) 1 (0) 1 (0) 1 (0)
Chromosome bands
0.166 0.1 0.65 (0.09) 0.55 (0.1) 0.78 (0.07) 0.63 (0.09) 0.64 (0.09)
0.5 0.9 (0.08) 0.67 (0.09) 0.98 (0.02) 0.83 (0.06) 0.83 (0.06)
1 0.98 (0.05) 0.72 (0.11) 0.95 (0.03) 0.93 (0.04) 0.93 (0.04)
0.5 0.1 0.72 (0.08) 0.60 (0.09) 0.90 (0.04) 0.70 (0.08) 0.70 (0.08)
0.5 0.99 (0.02) 0.88 (0.04) 1 (0) 0.95 (0.02) 0.93 (0.02)
1 1 (0.01) 0.94 (0.06) 1 (0) 0.99 (0.01) 0.99 (0.01)
0.84 0.1 0.76 (0.08) 0.62 (0.09) 0.93 (0.03) 0.74 (0.07) 0.74 (0.07)
0.5 1 (0.01) 0.93 (0.03) 1 (0) 0.98 (0.01) 0.96 (0.02)
1 1 (0) 0.99 (0.01) 1 (0) 1 (0) 0.99 (0)
Canonical pathways
0.166 0.1 0.56 (0.08) 0.55 (0.08) 0.71 (0.07) 0.58 (0.08) 0.57 (0.07)
0.5 0.70 (0.09) 0.70 (0.08) 0.87 (0.04) 0.78 (0.06) 0.76 (0.06)
1 0.82 (0.08) 0.82 (0.07) 0.87 (0.05) 0.88 (0.04) 0.86 (0.05)
0.5 0.1 0.60 (0.08) 0.61 (0.08) 0.80 (0.06) 0.66 (0.07) 0.64 (0.07)
0.5 0.81 (0.06) 0.82 (0.06) 0.92 (0.02) 0.89 (0.04) 0.87 (0.04)
1 0.91 (0.04) 0.92 (0.03) 0.93 (0.04) 0.94 (0.02) 0.92 (0.02)
0.84 0.1 0.62 (0.08) 0.63 (0.08) 0.82 (0.05) 0.70 (0.07) 0.68 (0.06)
0.5 0.84 (0.05) 0.85 (0.04) 0.93 (0.02) 0.91 (0.03) 0.90 (0.03)
1 0.93 (0.02) 0.94 (0.02) 0.94 (0.02) 0.95 (0.02) 0.93 (0.02)
Mean (and standard deviation) of the area under the ROC curve for selected values of the signal strength (b), and expected fraction of altered genes (g). E1,
single data type analysis using expression data; C1, single data type analysis using copy number data; INT, analysis of four data types using the integrative
method; AvgP and MinP, analysis of four data types using meta-analytical approach.
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Page 8 of 14discovers a large fraction of sets that are missed by all of
the one-dimensional analyses. Statistically, this means
that there is a large increase in the power to detect true
effects for a given list size. In general, it cannot be guar-
anteed that a set identified by a single-data-type analysis
will be necessarily identified using a model-based inte-
grative approach. Such a property applies to the mini-
mum P-value meta-analytical approach only when
significance is held constant. However, our analysis of
the ROC curves shows that our model-based integration
approach has the most favorable combination of sensi-
tivity and specificity.
Discussion
We have developed and compared general approaches
and specific tools to integrate data from genomic studies
that measure multiple genomic features in the same
subjects. Using simulations and data analysis, we
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Figure 3 True positive exclusively discovered sets. (a,b) The average fraction of true positive exclusively discovered sets by each of
traditional one-dimensional analysis (EF in Materials and methods section) (a) and integrative and meta-analytical methods (EF* in Materials and
methods section) (b). b = 0.5, g = 0.1. INT, integrative method.
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Page 9 of 14demonstrate how integration can discover important
patterns that would otherwise be missed.
Our methodology provides the greatest advantages
when genes within a set are altered by different mechan-
isms. Consider a pathway of ten genes, where one is
amplified, another is mutated, and a third is overex-
pressed. Single-data-type analysis and meta-analysis are
likely to miss this pathway, while an integrative
approach is poised to detect it. This does not come at
the price of overemphasizing the pathway’s importance
when there is redundancy in the signal. For example,
amplification and increased expression of a gene are
likely to be correlated. The integrative approach recog-
n i z e st h a tt h i si sas i n g l eb i o l o g i c a ls i g n a l .B o t he x p r e s -
sion and CN enter a single model for that gene, and the
two measurements will only do marginally better as a
pair than they would individually if they are highly
correlated.
Our approach will adjust for varying reliability across
data types: if the noise in a data type doubles, this data
type would automatically contribute less to each gene-
specific regression, and thus to the final result. Our
approach could be easily modified to allow users to
weight certain data types more heavily: for example, the
gene-specific regression could be estimated using Baye-
sian methods, where the information on the biological
importance of the data types is incorporated into prior
distributions for the coefficients.
Application to other phenotypes and inclusion of cov-
ariates are also straightforward, by suitably choosing the
type of regression used and the variables included. Cox
regression could be used for survival data, linear regres-
sion for continuous phenotypes. Sliced inverse regres-
sion [32] could also prove useful, since it can be directly
applied to both categorical and continuous phenotypes.
Importantly, our approach entails no additional price in
terms of multiple testing compared to one-dimensional
analysis.
We operate within a two-stage framework. There are
approaches for gene set analysis in other contexts that
operate directly on the raw data - for example, on
expression levels [33] or mutation counts [34]. These
approaches have the advantage of allowing for a fuller
treatment of uncertainty, some of which is lost by treat-
ing the regression-based scores as data. However, inte-
gration across platforms is greatly simplified by
operating on gene summaries. Our initial assumption
that each gene is measured once for each data type may
be overcome by adding as many terms to the linear pre-
dictor as there are measurements for the gene in ques-
tion, though additional investigation of this issue is
needed. Other approaches achieve integration by build-
ing a network that exploit existing knowledge on the
biological interactions within a pathway [35]. When
available, this can be very valuable information. On the
other hand, approaches considered here apply to far lar-
ger collections of gene sets - for example, positional
gene sets or collections of previously described prognos-
tic gene signatures - whose genes do not necessarily
have direct functional relationships.
The integrative approach is not readily extensible to
joint analysis of data when each data type is measured
in a different set of patients. However, for these studies,
meta-analytical approaches remain available. In our
simulations, spiked-in genes are selected independently
for each data type; therefore, the comparisons between
meta-analytical approaches and single platform analyses
are also applicable to situations where different data
types are measured in different subjects. Simulation
results show that the meta-analytical approach provides
improvements over the analysis performed using a single
data type, unless several data types present very strong
false positive results.
Lastly, application of the integrative approach to two
independent glioblastoma datasets has allowed us to dis-
cover and validate several gene sets associated with sur-
vival. These sets would not receive strong support when
expression and CN data are analyzed separately. The
role of some of the gene sets found with our approach
in GBM survival, such as pathways involved in sugar
metabolism, is strongly supported by recent literature.
Our suggestion of the previously unreported involve-
ment of the Wnt pathway in GBM survival provides
motivation for further, more in-depth biological
investigation.
Materials and methods
Statistical approaches for multi-platform analysis
Notation and problem definition
We begin by defining notation for the single data type
case. The data consist of a matrix of genomic measure-
ments X and a vector of phenotypes Y. The genomic
measurements are cross-referenced to a membership
matrix M whose generic element mgs is the indicator of
whether gene g is in set s. Many current gene set analy-
sis methods proceed in two stages [4,36-38]: gene-level
testing of differences between groups and set-level test-
ing of differences in scores.
In stage I (gene-level testing of differences between
groups), for each gene g, compute score sg(X,Y), captur-
ing the relationship between genomic measurements
and a phenotype.
In stage II (set-level testing of differences in scores),
using scores computed in stage I as data, look for associa-
tion between scores and columns of M. For example, by
testing whether the distribution of scores for genes in set
s is different from the distribution of scores for a refer-
ence group, say the set of all measured genes that are not
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titive test; or by comparing the observed distribution of sg
(X,Y), g Î s, to its null distribution, when genes are not
associated with the phenotype - the self-contained test.
Generalizing the setting of one-dimensional gene set
analysis, we assume that we have D dimensions to the
genomic investigation. Each dimension is a data type -
for example, transcript levels from expression arrays,
CN data, somatic mutations, methylation data. We
assume that the dimensions are available for the same
samples, and that the data provided in each dimension
are already summarized by gene.
Data are a series of D matrices of sample-specific
genomic measurements X
1,...,X
D and a vector/matrix of
phenotypes Y. These measurements are cross-referenced
to a single membership matrix M, as earlier.
Integrative approach
Heterogeneous data are integrated into a single gene-
specific score, followed by one-dimensional gene set
analysis. Formally, stage I consists of evaluating a score
sg(X
1,K,X
D ,Y) that draws from all the measurements
available from gene g across all the dimensions studied.
A relatively simple and general approach is to fit, for
every gene, a linear or generalized linear model of the
form:
φ(E(Yi|X1
gi,X2
gi,...,XD
gi)) =

d∈{1...D}
Xd
giβd
g
where  is a link function [39] and i the biological
sample. For each gene, the stage I score can be a mea-
sure of the overall fit of the model, for example, a likeli-
hood ratio for comparing this model to the ‘null’ model
in which all the βd
g coefficients are zero. In stage II
these scores can then be analyzed using traditional
methods to obtain set-specific scores ts(s,Ms).
Meta-analytical approach
This approach starts as a standard one-dimensional gene
set analysis: we determine gene-to-phenotype association
scores separately for each dimension and generate a
matrix of scores whose generic element is sd
g(Xd,Y),
and in stage II compute set-specific scores td
s (s,Ms),d Î
1,K, D, for each dimension. Next these scores can be
integrated, say, by averaging:
ts(s,Ms)= avg
d∈{1,...,D}
td
s (s,Ms),
when evidence of significance from several data types
is needed, or by taking an extremum:
ts(s,Ms)=extremum
d∈{1,...,D}
td
s (s,Ms),
when strong evidence from a single dimension is
sought.
Implementations
Single data type analysis
For each gene we compute the gene-to-phenotype asso-
ciation score as the difference of deviances of the logis-
tic regression models with and without the genomic
measurement as the single predictor. This score is used
in testing for gene sets that are enriched for genes dif-
ferent across phenotypes [4].
Integrative approach
For each gene, observations from all available data types
are used as independent variables in a multivariate logis-
tic regression model. The integrated gene-to-phenotype
association score is computed as the difference of the
deviances of the null model and the model with all pre-
dictors, and used in gene set tests. We denote this
implementation of the integrative approach by INT.
Meta-analytical approach
We use geometrically averaged P-values, AvgP [40], and
minimum P-values, MinP [41], from the single-data-type
gene set tests.
Gene set tests
We use the Mann-Whitney test, as implemented in the
R/Bioconductor package limma [30], for competitive
analysis, and the signed rank Wilcoxon test for self-con-
tained analyses. For the latter we generate the null dis-
tribution of gene-to-phenotype association scores by
permuting phenotype labels. We perform the test in 500
permutations, comparing the observed scores and null,
and then average the resulting test statistics; the P-
values are obtained from the critical values table of the
normal approximation to the Wilcoxon signed rank sta-
tistic. We compare discoveries across methods by
choosing the same P-value cutoff. The P-values would
remain comparable across methods if one applied a
multiple comparison adjustment, as the number of com-
parisons is the same in the integrative as in each of the
single-data-type approaches. While there are many
choices for the scores and gene set tests, the simple pro-
cedures we chose to implement perform very competi-
tively [4] and adequately represent the general gene set
enrichment approach in the context of our proposed
integration framework.
The Cancer Genome Atlas data
We consider TCGA glioblastoma data [2] of four types:
two gene expression measurements (E1, E2) using Affy-
metrix HT-HG-U133A and Agilent G4502A-07 micro-
arrays respectively; and two CN measurements (C1, C2),
both using the Agilent HG-CGH-244A platform but
performed in two different labs [42]. For expression, we
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CN, we average TCGA-normalized probe values by
gene; here we used the probe to gene mapping provided
by TCGA in the Array Definition Files. For simulations
we use 99 samples with randomly assigned binary phe-
notypes (49 and 50 observations per class). To discover
gene sets important in GBM survival we use an extreme
discordant phenotype design [9]. GBM patients with
survival time shorter than the lower quartile (190 days)
a r el a b e l e dS T S s ,a n dt h o s ew i t hs u r v i v a lt i m el o n g e r
than the upper quartile (594 days) LTSs. Such grouping
enhances signal relevant to survival. After removing
patients who developed a hypermutated phenotype due
to radiation treatment, we retained 95 observations (47
STS and 48 with LTS phenotypes). There are 12,042
genes for E1, 17,814 for E2, 21,814 for C1, and 23,167
for C2. The total number of genes measured in all data
types is 10,334, with 25,583 genes measured in at least
one.
For validation, we retrieved expression (Affymetrix
U133-Plus-2.0) and CN (Affymetrix 100K-SNP-Array)
data for 1,275 genes involved in the pathways discovered
in TCGA data analysis (see Results) from the
Rembrandt database [8]. Genes u m m a r i e sa r eo b t a i n e d
by averaging Rembrandt-preprocessed probe-level data.
We used 44 STS samples (survival ≤ 231 days), and 36
LTS samples (survival ≤ 775).
Simulations
We construct an empirical null scenario, where no
genes are associated with the phenotype, by randomly
assigning phenotype labels. This preserves correlations
between genes within data types, and correlations
between data types, yielding a realistic background dis-
tribution of gene-to-phenotype association scores. We
randomly select ten gene sets from a given gene set
collection for ‘spiking in’. For each spike-in set we ran-
domly select a fraction of its genes to be associated
with the phenotype. The number of genes that differ
across phenotypes is sampled from the binomial distri-
bution with parameter g, which reflects the desired
expected fraction of genes in a set to be associated
with the phenotype. For each selected gene we add Δk
to the observations for one of the phenotypes; Δki s
chosen so that, if the data were normal, with standard
deviation equal to the average standard deviation
among genes in the k-th spiked-in set, then the power
for the two-sample t-test would have value b. We call
b the signal strength.
We study the ability of the methods to discover
spiked-in sets as we vary b and g o nag r i d .T h es i g n a l
strength captures signal-to-noise ratio: at low values of
this parameter, gene-to-phenotype association scores for
t h es p i k e d - i ng e n e sw i l lb em o r es i m i l a rt ot h e i r
background null distribution. The expected fraction of
altered genes captures enrichment of such genes in a
spiked-in set. As this parameter grows, the distribution
of gene-to-phenotype association scores within a spiked-
in set is more likely to differ from the distribution of
t h es c o r e sf o rt h er e s to fg e n e s .W eu s eac o m p e t i t i v e
gene set test to evaluate this difference. Each simulation
scenario is repeated 1,000 times. Complete analysis on
each simulation repetition takes approximately 10 min-
utes wall-clock time on a MacBookPro 2.8 GHz Intel
Core 2 Duo with 4 GB RAM.
We compute the fraction of correctly discovered
spiked-in sets that are discovered with a given data type
but not by any of the other data types as:
EF(i)=1−
|

j∈S−i TP(j) ∩ TP(i) |
| TP(i) |
where i indexes data types: S={ E 1 , E 2 , C 1 , C 2 } , S-i is
the set of all data types excluding the i-th, and TP(·) is
the number of true positive sets among the top scoring
ones. For each of the three integration methods we also
compute the fraction of sets that are discovered exclu-
sively by that method:
EF∗(l)=1−
|

j∈S TP(j) ∩ TP(l) |
| TP(l) |
where l Î {INT,AvgP,MinP}, and S and TP(·) are
defined above.
All computations were performed in the statistical
software ‘R’ [5]. The R code used in our study is avail-
able as in Additional file 2. The code and R data objects
are also available for download online [43].
Additional material
Additional file 1: Tables with additional results for TCGA GBM data.
Table S1: P-values for the top 50 gene sets discovered by the integrative
method (INT) using the competitive gene set test. Patients from the
upper tertile of the survival distribution were labeled as long-term
survivors, and those from the lower tertile short-term survivors. Table S2:
P-values for the top 50 gene sets discovered by the integrative method
(INT) using the competitive gene set test. A Cox regression model was
used to establish gene-to-phenotype association scores.
Additional file 2: R code for methods described in the paper.A n
archive containing the R implementation of the methods described in
the paper, and used for simulations and data analysis.
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